Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Collins, A. Scrimgeour, S. Yusuf, R. Peto.
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin OverView of results of randomised trials in general, orthopedic and urologic surgery.
N Engl J Med, 318 (1988), pp. 1.162-1.173
[2.]
T.M. Hyers, R.D. Hull, J.G. Weg.
Antithrombotic therapy for venous Thromboembolic disease.
Chest, 102 (1992), pp. 408S-425S
[4.]
K.M. Moser.
Venous thromboembolism.
Am Rev Respir Dis, 141 (1990), pp. 235-249
[5.]
C. Thèry, J.J. Bauchart, M. Lesenne, P. Asseman, J.G. Flajollet, R. Legghe, et al.
Predictive factors of effectiveness of streptokinase in deep venous thrombosis.
Am J Cardiol, 69 (1992), pp. 117-122
[6.]
J. Hirsh.
Heparin..
N Engl J Med, 324 (1991), pp. 1.565-1.574
[7.]
M.N. Levine, J. Hirsh, S. Landefeld, G. Raskob.
Hemorragic complications of anticoagulant treatment.
Chest, 102 (1992), pp. 352S-363S
[8.]
R.D. Hull, G.E. Raskob, D. Rosembloom, J. Lemaire, G.F. Pineo, B. Baylis, et al.
Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
Arch Intern Med, 152 (1992), pp. 1.589-1.595
[9.]
R.D. Hull, G.E. Raskob, D. Rosenbloom, A.A. Panju, P. Brill-Edwards, J.S. Ginsberg, et al.
Heparin for five days as compared with ten days in the initial treatment of proximal venous thrombosis.
N Engl J Med, 322 (1990), pp. 1.260-1.264
[10.]
J. Hirsh, J.E. Dalen, D. Deykin, L. Poller.
Hepar Mechanism of action pharmacokinetics dosing considerations monitoring efficacy safety..
Chest, 102 (1992), pp. 337S-351S
[11.]
J.J. Heillman.
Traitment des thromboses veneuses profondes constituées..
Rev Med Interne, 10 (1989), pp. 375-381
[12.]
G. Simmoneau, B. Charbonier, H. Decousus, B. Planchon, J. Ninet, P. Sie, et al.
Subcutaneous low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.
Arch Intern Med, 153 (1993), pp. 1.541-1.546
[13.]
P. Prandoni, A.W. Lensing, H.R. Buller, M. Carta, A. Cogo, M. Vigo, et al.
Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
Lancet, 339 (1992), pp. 441-445
[14.]
R.D. Hull, G.E. Raskob, G.F. Pineo, D. Green, A.A. Trowbridge, G.G. Elliott, et al.
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
N Engl J Med, 326 (1992), pp. 975-982
[15.]
J. Hirsh.
Oral anticoagulants drugs.
N Engl J Med, 324 (1991), pp. 1.865-1.875
[16.]
S.Z. Goldhaber, M. Morpurgo.
Diagnosis, treatment, and prevention of pulmonary embolism Report of the WHO/International Society and Federation of Cardiology Task Force.
JAMA, 268 (1992), pp. 1.727-1.733
[17.]
M.D. Friedman.
Oral Anticoagulants: Pharmacodinamics, clinical indications and adverse effects.
J Clin Pharmacol, 32 (1992), pp. 196-209
[18.]
L.Q. Rogers, C.L. Lutcher.
Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature.
Am J Med, 88 (1990), pp. 389-395
[19.]
Tissue Plasminogen Activator for the Treatment of Acute Pulmonary Embolism:, A., Collaborative Study by the, PIOPED., Investigators.
Chest, 97 (1990), pp. 528-533
[20.]
Urokinase Pulmonary Embolism, Trial, A., cooperative study.
Phase 1 Results.
JAMA, 214 (1974), pp. 2.163-2.172
[21.]
Urokinase-Streptokinase Embolism Trial.
A cooperative study Phase 2 results..
JAMA, 229 (1974), pp. 1.606-1.613
[22.]
F. Schwarz, H. Stehr, R. Zimmerman, J. Manthey, W. Kubler.
Sustained improvement of pulmonary hemodinamics in patients a rest and during exercise after thrombolytic treatment of massive pulmonary embolism.
Circulation, 71 (1985), pp. 117-123
[23.]
G.V.R.K. Sharma, V.A. Burleron, A.A. Sasahara.
Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism.
N Engl J Med, 303 (1980), pp. 842-845
[24.]
B.A. Cooper, J.R. Leclerc.
OverView of Hemostasis and Blood Coagulation. Venous Thromboembolic Disorders., pp. 1-16
[25.]
J. Loscalzo, E. Braunwald.
Tissue Plasminogen Activator.
N Engl J Med, 319 (1988), pp. 925-931
[26.]
National Institutes of Health Consensus Panel Thrombolytic Therapy in Thrombosis:, A., National Institutes of Health Consensus Development Conference.
Ann Intern Med, 93 (1980), pp. 141-144
[27.]
A.A. Sasahara, C.A. St. Martin, J. Jenkin, W.M. Barker.
Approach the Patient with Venous Thromboembolism.
Treatment with Thrombolytic Agents. Hematology/Oncology Clinics of North America, 6 (1992), pp. 1.141-1.159
[28.]
D.R. Hirsch, S.Z. Goldhaber.
Bleeding Time and other Laboratory tests to Monitor the Safety and Efficacy of Thrombolytic Therapy.
Chest, 97 (1990), pp. 124S-131S
[29.]
A. Markel, R.A. Manzo, D.E. Strandness Jr..
The Potential Role of Thrombolytic Therapy in Venous Thrombosis.
Arch Intern Med, 152 (1992), pp. 1.265-1.267
[30.]
J.V. Marder, B. Brenner, S. Totterman, C.H.W. Francis, R. Rubin, A.K. Rao, et al.
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis.
J Lab Clin Med, 119 (1992), pp. 485-495
[31.]
P.F. Lawrence, G.R. Goodman.
Thrombolytic Therapy. Surgical Clinics of North America, 72 (1992), pp. 899-918
[32]
M. Rubenstein, W.P. Cruger.
Successful Streptokinase therapy for catheter-induced subclavian vein thrombosis.
Arch Intern Med, 140 (1980), pp. 1.370-1.371
[33]
E. Tovar, M. Marini, P. Díaz, S. Martínez, J.M. Castro, A. Gayoso, et al.
Fibrinólisis locorregional con Urokinasa en el tratamiento de la trombosis venosa profunda.
Angiología, 6 (1989), pp. 233-237
[34]
A.G.G. Turpie.
Thrombolytic therapy in venous thrombosis..
Thrombolysis Yearbook 1993 Amsterdam: Excerpta Medica, pp. 131-141
[35]
A.G.G. Turpie, M.N. Levine, J. Hirsh, J.S. Ginsberg, M. Cruickshank, R. Jay, et al.
Tissue plasminogen activator (rt-PA) vs heparin in thrombosis.
Results of a randomized trial. Chest, 97 (1990), pp. 172S-175S
[36]
M. Martin, B.J.O. Fiebach.
Short-therm ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thrombosis.
Semin Thromb Hemost, 17/1 (1991), pp. 21-38
[37]
S.Z. Goldhaber, M.F. Meyerovitz, D. Green, R.L. Vogelzang, P. Citrin, J. Heit, et al.
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
Am J Med, 88 (1990), pp. 235-240
[38]
R. Zimmerman, A. Gürsoy, A. Horm, J. Harenberg, C. Diehm, W. Kuble.
Fibrinolytic therapy of deep vein thrombosis with continuous intravenous of a recombinant tissue plasminogen activator.
Semin Thromb Hemostasis, 17/1 (1991), pp. 48-54
[39]
V.J. Marder, S. Sherry.
Thrombolytic Therapy: Current Status (Second of two parts).
N Engl J Med, 318 (1988), pp. 1.585-1.595
[40]
S. Sherry.
Thrombolytic Therapy for Acute Pulmonary Embolism.
Fibrinolysis, Thrombosis and Hemostasis., pp. 229-230
[41]
R.D. Anderson, M.N. Levine.
Thrombolytic therapy for the treatment of acute pulmonary embolism.
Can Med Assoc J, 146 (1992), pp. 1.317-1.324
[42]
J.A. Parker, J.E. Markis, A. Palla, et al.
Early improvement in pulmonary perfusion after rt-PA therapy for acute embolism: segmental perfusion sean analysis.
Radiology, 166 (1988), pp. 441-445
[43]
G. Agnelli.
Rationale for bolus t-PA therapy to improve efficacy and safety.
Chest, 97 (1990), pp. 161S-167S
[44]
M.N. Levine, J. Hirsh, J. Weitz, M. Cruickshank, J. Neemen, A.G. Turpie, et al.
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Chest, 98 (1990), pp. 1.473-1.479
[45]
G. Pacouret, B. Charbonnier, B. Delahousse, P. Fournier.
Pilot study of a 50 mg over 10 minutes alteplase regimen in massive pulmonary embolism [resumen]., J Am Coll Cardiol.
, 19 (1992), pp. 315A
[46]
PIOPED., investigators.
Value of the ventilation/perfusion scan in acute pulmonary embolism Results of the Investigation of Pulmonary Embolism Diagnosis (PIOPED).
J Am Med Assoc, 263 (1990), pp. 2.753-2.759
Copyright © 1994. Sociedad Española de Neumología y Cirugía Torácica
